Literature DB >> 9147492

Impaired antioxidant defense at the onset of psychosis.

S Mukerjee1, S P Mahadik, R Scheffer, E E Correnti, H Kelkar.   

Abstract

Previous studies found peripheral activities of antioxidant enzymes to be abnormal in schizophrenic patients. It is not understood whether this is integral to the disease process or a result of long-term treatment with neuroleptics. Red blood cell activities of three antioxidant enzymes--superoxide dismutase, glutathione peroxidase, and catalase--were therefore examined in 14 drug-naive, first episode patients with a diagnosis of schizophrenia or schizophreniform disorder and 10 normal subjects. The patients had an average duration of psychosis of 4.46 days (SD 2.5). Superoxide dismutase activity was significantly lower in patients than in normal controls, with no difference between the groups in activities of the other two enzymes. Lower superoxide dismutase activity was associated with deterioration of school functioning from childhood to early adolescence and a history of poorer school functioning during early adolescence. These findings indicate a compromised antioxidant defense at the onset of psychosis, and suggest that oxidative injury might contribute to adverse developmental events in the pathogenic cascade of schizophrenia.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9147492     DOI: 10.1016/0920-9964(95)00048-8

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  29 in total

1.  Validation of glutathione quantitation from STEAM spectra against edited 1H NMR spectroscopy at 4T: application to schizophrenia.

Authors:  Melissa Terpstra; T J Vaughan; Kamil Ugurbil; Kelvin O Lim; S Charles Schulz; Rolf Gruetter
Journal:  MAGMA       Date:  2005-11-18       Impact factor: 2.310

Review 2.  Oxidative stress in schizophrenia: an integrated approach.

Authors:  Byron K Y Bitanihirwe; Tsung-Ung W Woo
Journal:  Neurosci Biobehav Rev       Date:  2010-10-23       Impact factor: 8.989

Review 3.  Antioxidants, redox signaling, and pathophysiology in schizophrenia: an integrative view.

Authors:  Jeffrey K Yao; Matcheri S Keshavan
Journal:  Antioxid Redox Signal       Date:  2011-04-21       Impact factor: 8.401

Review 4.  Oxidative damage and schizophrenia: an overview of the evidence and its therapeutic implications.

Authors:  J K Yao; R D Reddy; D P van Kammen
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

5.  N-Acetyl cysteine reverses social isolation rearing induced changes in cortico-striatal monoamines in rats.

Authors:  Marisa Möller; Jan L Du Preez; Francois P Viljoen; Michael Berk; Brian H Harvey
Journal:  Metab Brain Dis       Date:  2013-09-03       Impact factor: 3.584

6.  Role of oxidative stress in the pathophysiology of Toxoplasma gondii infection.

Authors:  Gungor Cagdas Dincel; Hasan Tarik Atmaca
Journal:  Int J Immunopathol Pharmacol       Date:  2016-03-10       Impact factor: 3.219

7.  Cognitive function, plasma MnSOD activity, and MnSOD Ala-9Val polymorphism in patients with schizophrenia and normal controls.

Authors:  Xiang Y Zhang; Da C Chen; Mei H Xiu; Fu D Yang; Yunlong Tan; Xingguang Luo; Lingjun Zuo; Therese A Kosten; Thomas R Kosten
Journal:  Schizophr Bull       Date:  2013-04-15       Impact factor: 9.306

8.  Social isolation exacerbates schizophrenia-like phenotypes via oxidative stress in cortical interneurons.

Authors:  Zhihong Jiang; Gregory R Rompala; Shuqin Zhang; Rita M Cowell; Kazu Nakazawa
Journal:  Biol Psychiatry       Date:  2013-01-21       Impact factor: 13.382

9.  Meta-analysis of oxidative stress in schizophrenia.

Authors:  Joshua Flatow; Peter Buckley; Brian J Miller
Journal:  Biol Psychiatry       Date:  2013-05-15       Impact factor: 13.382

10.  Superoxide dismutase and cytokines in chronic patients with schizophrenia: association with psychopathology and response to antipsychotics.

Authors:  Xiang Yang Zhang; Dong Feng Zhou; Ling Yan Qi; Song Chen; Lian Yuan Cao; Da Chun Chen; Mei Hong Xiu; Fan Wang; Gui Ying Wu; Lin Lu; Therese A Kosten; Thomas R Kosten
Journal:  Psychopharmacology (Berl)       Date:  2009-01-13       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.